华润医药(03320.HK) 公布，集团旗下华润双鹤利民收到国家药监局颁发的法莫替丁注射液《药品补充申请批准通知书》，并视同通过一致性评价。同时，集团旗下双鹤利民获得河南省药品监督管理局颁发的《药品GMP符合性检查告知书》，通过药品GMP符合性检查。
法莫替丁为组织胺H2受体拮抗剂，能够抑制胃酸分泌，该药品主要用于消化性溃疡所致上消化道出血，除肿瘤及食道、胃底静脉曲张以外的各种原因所致的胃及十二指肠粘膜糜烂出血者。根据国家药监局信息显示，内地境内已批准上市的法莫替丁注射液共有46家企业，其中通过或视同通过一致性评价的生产企业21家。另外，双鹤华利新建的生产线E线为首次获批通过GMP符合性检查，C1线及C2线早前已通过GMP符合性检查。(vc/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-06 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.